Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing

D Blom1, M Ermers, L Bont

  • 1Emma Children's Hospital, Pediatrics, Meibergdreef 9, Amsterdam, Netherlands, 1105 AZ. d.j.blom@amc.uva.nl

Insights

Inhaled corticosteroids administered during acute bronchiolitis do not prevent post-bronchiolitic wheezing in infants. This review found no significant effect on wheezing, hospital readmissions, or medication use, despite no reported adverse events.

Area of Science:

  • Pediatric Respiratory Medicine
  • Clinical Immunology
  • Evidence-Based Medicine

Background:

  • Acute bronchiolitis is linked to long-term airway issues like post-bronchiolitic wheezing (PBW).
  • Two hypotheses explain this link: bronchiolitis as an early sign of susceptible children or airway injury from infection causing PBW.
  • Corticosteroids are hypothesized to prevent PBW by mitigating inflammation-induced airway injury.

Purpose of the Study:

  • To assess the efficacy of inhaled corticosteroids in preventing post-bronchiolitic wheezing when initiated during acute bronchiolitis.

Main Methods:

  • A systematic review of randomized placebo-controlled trials involving infants under two with acute bronchiolitis.
  • Searches included major databases (CENTRAL, MEDLINE, EMBASE) and congress abstracts; experts and pharmaceutical companies were also consulted.
  • Data extraction and quality assessment (Jadad scale) were performed independently by two authors.

Main Results:

  • Five trials involving 374 infants met the criteria; median Jadad score was 4.
  • Pooled data showed no significant effect of inhaled corticosteroids on preventing wheezing, hospital readmissions, or subsequent medication use.
  • Analysis indicated that duration of therapy, follow-up length, or causative agent did not alter the outcomes; no adverse events were reported.

Conclusions:

  • Current evidence does not support the use of inhaled corticosteroids during acute bronchiolitis for preventing post-bronchiolitic wheezing.
  • The limited number of participants and heterogeneity of studies prevent definitive recommendations.
Abstract

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: